Pharma Equity Group A/S (CPH:PEG)

Market Cap	126.44M
Revenue (ttm)	n/a
Net Income (ttm)	-21.02M
Shares Out	1.23B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,262,791
Average Volume	835,504
Open	0.1040
Previous Close	0.1025
Day's Range	0.1025 - 0.1050
52-Week Range	0.0706 - 0.1905
Beta	0.94
RSI	40.78
Earnings Date	Nov 14, 2025

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG